Evidence map›Paper›PMID 28941090›Full record

ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2017

Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys.

Louisa Degenhardt, Meyer Glantz, Sara Evans-Lacko, Ekaterina Sadikova, Nancy Sampson, Graham Thornicroft, Sergio Aguilar-Gaxiola, Ali Al-Hamzawi, Jordi Alonso, Laura Helena Andrade and 28 more

Open access · bronzeAbstract read
In one paragraph

Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 7 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 7 syntheses or guidelines pooled it, 273 citations in OpenAlex.

  1. Substance Use Disorder Treatment Outcomes: Methodological Overview of Metrics and Criteria.International journal of methods in psychiatric research · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 20 institutions in 25 countries.

Louisa DegenhardtNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
Meyer GlantzDivision of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Sara Evans-LackoCentre for Global Mental Health, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Ekaterina SadikovaDepartment of Health Care Policy, Harvard Medical School, Boston, MA, USA.
Nancy SampsonDepartment of Health Care Policy, Harvard Medical School, Boston, MA, USA.
Graham ThornicroftCentre for Global Mental Health, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Sergio Aguilar-GaxiolaCenter for Reducing Health Disparities, UC Davis Health System, Sacramento, CA, USA.
Ali Al-HamzawiCollege of Medicine, Al-Qadisiya University, Diwaniya Governorate, Iraq.
Jordi AlonsoHealth Services Research Unit, Hospital del Mar Medical Research Institute; Pompeu Fabra University; and CIBER en Epidemiología y Salud Pública, Barcelona, Spain.
Laura Helena AndradeSection of Psychiatric Epidemiology, Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.
Ronny BruffaertsUniversitair Psychiatrisch Centrum - Katholieke Universiteit Leuven, Campus Gasthuisberg, Leuven, Belgium.
Brendan BuntingSchool of Psychology, Ulster University, Londonderry, UK.
Evelyn J BrometDepartment of Psychiatry, Stony Brook University School of Medicine, Stony Brook, NY, USA.
José Miguel Caldas de AlmeidaChronic Diseases Research Center and Department of Mental Health, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.
Giovanni de GirolamoIRCCS S. Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Silvia FlorescuNational School of Public Health, Management and Professional Development, Bucharest, Romania.
Oye GurejeDepartment of Psychiatry, University College Hospital, Ibadan, Nigeria.
Josep Maria HaroParc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain.
Yueqin HuangInstitute of Mental Health, Peking University, Beijing, China.
Aimee KaramInstitute for Development, Research, Advocacy and Applied Care, Beirut, Lebanon.
Elie G KaramInstitute for Development, Research, Advocacy and Applied Care, Beirut, Lebanon.
Andrzej KiejnaWroclaw Medical University, University of Lower Silesia, Wroclaw, Poland.
Sing LeeDepartment of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong.
Jean-Pierre LepineHôpital Lariboisière Fernand Widal, Assistance Publique Hôpitaux de Paris INSERM UMR-S 1144, Paris Diderot and Paris Descartes Universities, Paris, France.
Daphna LevinsonMental Health Services, Ministry of Health, Israel.
Maria Elena Medina-MoraNational Institute of Psychiatry Ramón de la Fuente, Mexico City, Mexico.
Yosikazu NakamuraDepartment of Public Health, Jichi Medical University, Shimotsuke, Japan.
Fernando Navarro-MateuSubdirección General de Planificación, Innovación y Cronicidad, Servicio Murciano de Salud, Murcia, Spain.
Beth-Ellen PennellInstitute for Social Research, University of Michigan, Ann Arbor, MI, USA.
José Posada-VillaColegio Mayor de Cundinamarca University, Bogota, Colombia.
Kate ScottDepartment of Psychological Medicine, University of Otago, Dunedin, Otago, New Zealand.
Dan J SteinDepartment of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
Margreet Ten HaveNetherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands.
Yolanda TorresCenter for Excellence on Research in Mental Health, CES University, Medellin, Colombia.
Zahari ZarkovDirectorate for Mental Health, National Center of Public Health and Analyses, Sofia, Bulgaria.
Somnath ChatterjiDepartment of Information, Evidence and Research, World Health Organization, Geneva, Switzerland.
Ronald C KesslerDepartment of Health Care Policy, Harvard Medical School, Boston, MA, USA.
World Health Organization's World Mental Health Surveys collaborators
Harvard University · USKing's College London · GBCentro de Investigación Biomédica en Red de Salud Mental · ESCentro San Giovanni di Dio Fatebenefratelli · ITChinese University of Hong Kong · HKInserm · FRInstitute for Development, Research, Advocacy and Applied Care · LBInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz · MXIsrael Ministry of Health · ILJichi Medical University · JPNational Center of Public Health and Analyses · BGNational Institutes of Health · USNational School of Public Health, Management and Professional Development · ROPeking University · CNServicio Murciano de Salud · ESStony Brook School · USUC Davis Health · USUniversidad CES · COUniversidad Colegio Mayor de Cundinamarca · COUniversidade de São Paulo · BR

Funding

Risk Factors for Psychopathology in the WHO WMH SurveysR01MH070884 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KESSLER, RONALD C · 2005 to 2009
$6.0M
Social Role Disability and Mental-Physical Co-MorbidityR01MH069864 · NIMH · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI VON KORFF, MICHAEL R · 2004 to 2007
$2.2M
CROSS-NATIONAL STUDIES OF DRUG INVOLVEMENT: WMH2000R01DA016558 · NIDA · MICHIGAN STATE UNIVERSITY · PI ANTHONY, JAMES CHRISTOPHER · 2003 to 2008
$1.7M
World Mental Health Consortium Annual Meeting 2003-07R13MH066849 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HEERINGA, STEVEN G · 2003 to 2007
$735k
World Mental Health Consortium Annual Meetings 2008-2012U13MH066849 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HEERINGA, STEVEN G · 2008 to 2012
$647k
Lebanon-Epidemiology: The NCS Replication StudyR03TW006481 · FIC · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KESSLER, RONALD C · 2004 to 2006
$142k
FIC NIH HHS R03 TW006481NIDA NIH HHS R01 DA016558NIMH NIH HHS R01 MH069864NIMH NIH HHS R01 MH070884NIMH NIH HHS R13 MH066849NIMH NIH HHS U13 MH066849World Health Organization 001
6 · The paper itself

Abstract

Substance use is a major cause of disability globally. This has been recognized in the recent United Nations Sustainable Development Goals (SDGs), in which treatment coverage for substance use disorders is identified as one of the indicators. There have been no estimates of this treatment coverage cross-nationally, making it difficult to know what is the baseline for that SDG target. Here we report data from the World Health Organization (WHO)'s World Mental Health Surveys (WMHS), based on representative community household surveys in 26 countries. We assessed the 12-month prevalence of substance use disorders (alcohol or drug abuse/dependence); the proportion of people with these disorders who were aware that they needed treatment and who wished to receive care; the proportion of those seeking care who received it; and the proportion of such treatment that met minimal standards for treatment quality ("minimally adequate treatment"). Among the 70,880 participants, 2.6% met 12-month criteria for substance use disorders; the prevalence was higher in upper-middle income (3.3%) than in high-income (2.6%) and low/lower-middle income (2.0%) countries. Overall, 39.1% of those with 12-month substance use disorders recognized a treatment need; this recognition was more common in high-income (43.1%) than in upper-middle (35.6%) and low/lower-middle income (31.5%) countries. Among those who recognized treatment need, 61.3% made at least one visit to a service provider, and 29.5% of the latter received minimally adequate treatment exposure (35.3% in high, 20.3% in upper-middle, and 8.6% in low/lower-middle income countries). Overall, only 7.1% of those with past-year substance use disorders received minimally adequate treatment: 10.3% in high income, 4.3% in upper-middle income and 1.0% in low/lower-middle income countries. These data suggest that only a small minority of people with substance use disorders receive even minimally adequate treatment. At least three barriers are involved: awareness/perceived treatment need, accessing treatment once a need is recognized, and compliance (on the part of both provider and client) to obtain adequate treatment. Various factors are likely to be involved in each of these three barriers, all of which need to be addressed to improve treatment coverage of substance use disorders. These data provide a baseline for the global monitoring of progress of treatment coverage for these disorders as an indicator within the SDGs.

Indexed as

alcoholdrugsSubstance use disorderstreatment coverageUnited Nations Sustainable Development GoalsWorld Health Organization

Identifiers

PMID28941090
PMCPMC5608813
OpenAlexW2760464711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.